Tackling the Ridgeway Trail

Hear from one of our members, Clive, who along with two of his friends, walked the Ridgeway National Trail to raise money for Macmillan Cancer Support. “I have known Dave all my life. From the age of 4. Kim, since we were 24.  Dave was the first. He was diagnosed  with early prostate cancer about […]

Dr Steve Allen appointed as Acting Chair

Steve Allen

Tackle Prostate Cancer is pleased to announce the appointment of Dr Steve Allen as Acting Chair, following the recent departure of Ken Mastris. Steve was appointed as a Trustee in February 2022 and was voted into the position of Acting Chair by the Board of Trustees on the 4th of March 2022. Over the last […]

New campaign launches to break down taboos around prostate cancer treatment side effects

Let's Talk About the Hard Things Campaign

New campaign launches to break down taboos around prostate cancer treatment side effects http://www.pcr.org.uk/hard-things Prostate cancer is the most diagnosed cancer in the UK, with 57,192 men diagnosed in 2019 —equating to 1 man every 9 minutes.[i] New research shows 86% of men receiving treatment for prostate cancer experienced erectile dysfunction, and 79% suffered a […]

Letter from Chairman Ken Mastris

Dear friends and colleagues I hope you and your families are all keeping well and safe. We have all gone through a difficult time in 2020 and the start of this year is showing little improvement. Last year I lost my mother, who was 100, but as the circle of life goes gained a granddaughter […]

NICE and SMC approve Darolutamide to revolutionise the treatment of progressing prostate cancer

Prostate cancer charity Tackle is distraught as NICE slashes more drug availability – now for Abiraterone

The National Institute for Clinical Excellence (NICE) and the Scottish medicines Commission (SMC) have both now approved the use of a new drug, Darolutamide, as an option for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease. This stage of the disease is variably described as: Non-metastatic castrate resistant prostate cancer […]

NICE approve Darolutamide to revolutionise the treatment of progressing prostate cancer

Prostate Cancer Diagnosis

The National Institute for Clinical Excellence (NICE) has just approved the use of a new drug, Darolutamide, as an option for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease. This stage of the disease is variably described as: Non-metastatic castrate resistant prostate cancer Non-metastatic hormone resistant prostate cancer Non-metastatic hormone […]

Tackle Prostate Cancer Appoints Sarah Gray as National Support & Development Manager

Tackle Prostate Cancer charity, the voice of prostate cancer patients and their families in the UK is delighted to announce the appointment of Sarah Gray as its new National Support and Development Manager. The charity has been awarded funding by the National Lottery for the project Tackling Prostate Cancer – peer-to-peer support for men with prostate […]

Appeal application against NICE decision accepted

Tackle makes submission to NHS England Cancer Taskforce on 5-Year Strategy for Cancer

Steve Allen, Tackle Patient Representative, reports that the combined application for appeal against the NICE decision on Abiraterone made by Tackle and Prostate Cancer UK has been successful. A submission made by Prof Nick James, a nominated clinical expert, has also been accepted. This is merely a first step in a long process. It does […]